Trilo Therapeutics
Private Company
Total funding raised: $5M
Overview
Trilo Therapeutics is pioneering a new modality in targeted oncology with its Trilomer® platform, which utilizes DNA-encoded libraries to discover macrocyclic D-peptide drug conjugates. These molecules are engineered for superior tumor penetration, protease resistance, and reduced renal uptake compared to antibodies and L-peptides, potentially offering a safer and more effective delivery vehicle for cytotoxic payloads. The company is in active preclinical development against several clinically validated ADC targets, positioning itself to address significant unmet needs in cancer therapy. As a private, pre-revenue entity, its success hinges on advancing its lead candidates into clinical trials and validating its platform's advantages.
Technology Platform
The Trilomer® Discovery Platform is a proprietary DNA-encoded library (DEL) technology for synthesizing and screening billions of macrocyclic peptides composed of 100% D-amino acids. It enables rapid discovery of long-chain (10-15+ residue), cyclized peptidomimetics that are protease-resistant, non-immunogenic, and exhibit low renal uptake. These molecules are designed as targeted drug conjugates for oncology.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Trilo competes in the crowded targeted cancer therapy arena against established ADC developers (e.g., AstraZeneca, Daiichi Sankyo, Genmab/Seagen) and numerous biotechs developing next-generation ADCs, alternative scaffolds (e.g., bicyclic peptides, DARPins), and peptide-drug conjugates. Its differentiation hinges on proving superior pharmacokinetics and tissue distribution from its small, D-amino acid-based constructs.